Shanghai Medicilon Inc. (688202)

Overview

Shanghai Medicilon Inc. is a drug discovery contract research organization (CRO) that extends its services to both pharmaceutical and biotechnology companies across the globe, including China. Since its inception in 2004, with its headquarters nestled in Shanghai, China, the company has been instrumental in providing an extensive range of services that cover the entire spectrum of drug discovery and development. This firm stands out for its commitment to aiding companies in advancing their drug discovery projects from conceptual stages to the market by offering comprehensive services that span across chemistry, drug formulation, biology, pharmacology, and preclinical trials.

Products and Services

• Chemistry Services: The company offers an exhaustive suite of chemistry services that encompasses medicinal chemistry, synthesis, analytical chemistry, and process development services. These services are foundational in drug discovery and development, facilitating the creation and optimization of compounds with potential therapeutic effects.
• Drug Formulation Services: Focused on pre-formulation and analytical development services, Shanghai Medicilon Inc.'s drug formulation services also include research on quality control and clinical trial material services. These are critical in determining the appropriate form and delivery mechanism for pharmaceutical compounds, ensuring their stability, efficacy, and safety.
• Biology Services: Offering a wide array of biology services such as recombinant protein services, crystallization and structural services, discovery biology, computational biology and molecular modeling, and kinase services. The company also provides prepackaged M9 selenomethionine growth media kits and packages for IPTG-inducible bacterial expression systems, which are essential in studying protein structures and functions, facilitating the identification of potential drug targets.
• Pharmacology Services: Medicilon delivers pharmacology services that cover a range of disease models including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, among others. Additionally, it provides extensive services in in vitro ADME and in vivo pharmacokinetics, along with bioanalytical services for both large and small molecules. These services are crucial for understanding the pharmacological effects and kinetics of drug candidates in biological systems.
• Preclinical Services: The company extends preclinical services that include pharmacokinetic and safety evaluation. These services are vital in assessing the safety and efficacy profile of drug candidates before advancing to clinical trials, ensuring compliance with regulatory standards and reducing the risk of late-stage failures.